Literature DB >> 1483793

The quest for an animal model of high altitude pulmonary edema.

R B Schoene1, S Goldberg.   

Abstract

The understanding of the mechanisms underlying certain human diseases usually requires an animal model which can be manipulated in a way that will allow dissection of the pathophysiologic events which lead to the disease. High altitude pulmonary edema (HAPE) occurs in some healthy individuals who ascend from low to high altitude. The disease is characterized by a high protein leak into the lungs and is associated with accentuated pulmonary hypertension. Attempts to find an animal model for HAPE have been made in a number of animal species, including rats, rabbits, sheep, dogs and ferrets. None has been consistently successful. Utilizing the physiologic characteristic of an accentuated hypoxic pulmonary vascular response, we studied both pigs and rats during the stresses of hypoxia and exercise (rats) and examined the lungs for the cellular, protein, and morphologic changes. Protein and cell contents in the lung lavage of the hypoxic animals were slightly higher than the controls while the presence of von Willebrand factor in the hypoxic animals suggests early epithelial damage. This presentation will review previous attempts to find an animal model of HAPE and will discuss the preliminary results of our studies with their suggestive but not confirmatory results.

Entities:  

Mesh:

Year:  1992        PMID: 1483793     DOI: 10.1055/s-2007-1024595

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  2 in total

Review 1.  High altitude pulmonary oedema: still a place for controversy?

Authors:  J P Richalet
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

2.  Pulmonary edema and pleural effusion in norepinephrine-stimulated rats--hemodynamic or inflammatory effect?

Authors:  Beate Rassler; Christian Reissig; Wilfried Briest; Andrea Tannapfel; Heinz-Gerd Zimmer
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.